An Open-Label Phase 1b Study Evaluating the Safety and Efficacy of ABBV-383 in AL Amyloidosis
Study of ABBV-383 in Patients with Amyloidosis
Sponsor: AbbVie
Enrolling: Male and Female Patients
IRB Number: AAAV0515
U.S. Govt. ID: NCT06158854
Contact: Research Nurse Navigator: 212-342-5162 /
Additional Study Information: The purpose of this study is to see how safe and effective is the study drug, ABBV-383. ABBV-383 works by binding to a specific protein called B-cell maturation antigen, which is found on the surface of cells affected by amyloidosis. By engaging T-cells, a type of white blood cell, ABBV-383 helps activate the immune response to target and remove the abnormal proteins that cause amyloidosis. The study drug ABBV-383, is not approved by the U.S Food and Drug Administration (FDA).
Rajshekhar Chakraborty, MD
Do You Qualify?
Are you at least 18 years old? Yes No
Have you been diagnosed with amyloidosis? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Research Nurse Navigator